STEPHEN J TAPSCOTT
Neurology at Eastlake Ave, Seattle, WA

6444463, Sep 3, 2002

Feb 7, 2000

09/499227

Stephen J. Tapscott - Seattle WA

Fred Hutchinson Cancer Research Center - Seattle WA

C12N 1500

435325, 4353201, 435455, 536 231, 536 235, 536 2431

Provided are methods of classifying and prognosticating human neuroectodermal tumors by analyzing a sample of the tumor to determine whether various bHLH proteins are detectably expressed in the sample. In the methods disclosed herein, expression of the bHLH genes is assessed by measuring transcripts or proteins expressed from the genes.

2013028, Oct 31, 2013

Aug 18, 2011

13/817531

Silvere M. van der Maarel - Leiden, NL
Stephen J. Tapscott - Seattle WA, US
Rabi Tawil - Rochester NY, US
Richard J.L.F. Lemmers - Leiden, NL
Linda Geng - Seattle WA, US
Lauren Snider - Seattle WA, US

Fred Hutchinson Cancer Research Center - Seattle WA
University of Rochester Medical Center - Rochester NY
Leiden University Medical Center - Leiden

C12Q 1/68, G01N 33/68

514 177, 435 611, 435 612, 435 792, 435 613, 536 2433, 536 2431, 514 44 R

In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene, wherein a determination of the absence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject does not have a genetic predisposition to develop, and is not suffering from FSHD, and/or wherein a determination of the presence of a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene indicates that the subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD).

2010027, Oct 28, 2010

May 26, 2009

12/472311

Stephen J. Tapscott - Seattle WA, US
Hisashi Tanaka - Pepper Pike OH, US
Meng-Chao Yao - Taipei, TW
Scott J. Diede - Seattle WA, US

Fred Hutchinson Cancer Research Center - Seattle WA

C12Q 1/68

435 6

The present disclosure provides methods for detecting the genome-wide presence of methylated DNA and palindrome formation. The present disclosure also provides methods for specific enrichment of methylated DNA or DNA having a DNA palindrome. These methods have demonstrated that somatic palindromes and methylated DNA occur frequently and are widespread in human cancers. Individual tumor types have a characteristic non-random distribution of palindromes in their genome and a small subset of the palindromic loci are associate with gene amplification. The disclosed method can be used to define the plurality of genomic DNA palindromes and regions having methylated DNA associated with various tumor types and can provide methods for the classification of tumors, and the diagnosis, early detection of cancer as well as the monitoring of disease recurrence and assessment of residual disease.

8597880, Dec 3, 2013

Oct 2, 2008

12/681433

Stephen J. Tapscott - Seattle WA, US
Galina N. Filippova - Seattle WA, US
Paula D. Ladd - Seattle WA, US

The Fred Hutchinson Cancer Research Center - Seattle WA

C12Q 1/68, C12P 19/34, C07H 21/02, C07H 21/04

435 61, 435 912, 536 231, 536 243

The present invention provides compositions and methods of identifying a subject as having an increased risk of developing fragile X-associated tremor and ataxia syndrome (FXTAS) or identifying a subject having an increased risk of developing fragile X syndrome (FXS), comprising analyzing messenger RNA (mRNA) transcripts and/or translation products of the antisense gene ASFMR1.

5352595, Oct 4, 1994

Sep 3, 1991

7/753520

Stephen J. Tapscott - Seattle WA
Harold M. Weintraub - Seattle WA
Theodore D. Palmer - Kirkland WA

Fred Hutchinson Cancer Research Center - Seattle WA

C12N 510, C12N 1511, C12N 1585

4351723

Isolated DNA or RNA molecules capable of hybridizing under stringent conditions to the myoD regulatory region, its proximal promoter and distal enhancer regulatory regions, and regulatory elements within the proximal and distal regions for binding basic helix-loop-helix proteins, MyoD, and proteins binding at SP1, AP1, CAAT, M-CAT, CArG, and MEF sites in DNA. DNA or RNA expression vectors for introducing a gene into a cell under the regulatory control of the myoD regulatory region. Transduced or transfected pre-muscle cells, myocytes, or myoblasts. Methods of inducing a muscle phenotype in a non-muscle cell, positively selecting for a cells expressing MyoD, and negatively selecting for cells expressing MyoD.

5695995, Dec 9, 1997

Nov 2, 1995

8/552142

Harold M. Weintraub - late of Seattle WA
Jacqueline E. Lee - Denver CO
Stanley M. Hollenberg - Portland OR
Stephen J. Tapscott - Seattle WA

Fred Hutchinson Cancer Research Center - Seattle WA

C12N 1585, C12N 510, C12N 1518

435325

Neurogenic differentiation genes and proteins are identified, isolated, and sequenced. Expression of neuroD has been demonstrated in neural, pancreatic, and gastrointestinal cells. Ectopic expression of neuroD in non-neuronal cells of Xenopus embryos induced formation of neurons.

5795723, Aug 18, 1998

Aug 7, 1997

8/910973

Stephen J. Tapscott - Seattle WA
James M. Olson - Seattle WA

Fred Hutchinson Cancer Research Center - Seattle WA

C12Q 168, C12Q 104, C12P 2102, C07H 2104

435 6

Provided are methods of classifying and prognosticating human neuroectodermal tumors by analyzing a sample of the tumor to determine whether various bHLH proteins are detectably expressed in the sample. In the methods disclosed herein, expression of the bHLH genes is assessed by measuring transcripts or proteins expressed from the genes.